University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, 703 00, Czech Republic.
Palacky University & University Hospital Olomouc, Olomouc, 771 47, Czech Republic.
Future Oncol. 2021 Jul;17(19):2499-2512. doi: 10.2217/fon-2020-1225. Epub 2021 Mar 26.
To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. NCT02761187 (ClinicalTrials.gov).
评估伊沙佐米-来那度胺-地塞米松（IRd）在常规临床实践中治疗复发/难治性多发性骨髓瘤的疗效和安全性。对来自全球观察性 INSIGHT-MM 研究和捷克单克隆丙种球蛋白血症登记处的患者水平数据进行整合和分析。在数据截止时，来自 13 个国家的 263 名患者被纳入分析。从诊断到开始 IRd 的中位时间为 35.8 个月；中位随访时间为 14.8 个月。总缓解率为 73%，中位无进展生存期为 21.2 个月，下次治疗时间为 33.0 个月。17%/36%的患者需要减少伊沙佐米/来那度胺的剂量；由于不良反应，32%/30%的患者停止使用伊沙佐米/来那度胺。IRd 在常规临床实践中的疗效和安全性与 TOURMALINE-MM1 研究报告的结果相当。NCT02761187（ClinicalTrials.gov）。
